Corporate News
Posted On Tuesday, January 15, 2008 at at 11:33 AM by Finance AnalysisASIAN MARKETS
Asian markets, with the exception of
Ellipsiz warned that profit for H1 ended Dec ’07 will be “significantly lower” than a year ago, when the profit was a robust $10.89 mln. (Profit in H2 ended Jun ’07 had already slipped to $4.14 mln.) Ellipsiz has also appointed Melvin Chan as the new CEO, as Xavier Chong gives up the role to remain as Executive Chairman. Ellipsiz’s share price has dropped 70% since the prospective buyer terminated talks with the company in June; at 30.5 cents, Ellipsiz is at its lowest since 2003.
Even though the Temasek name would help STATS borrow cheaply, investors were certainly not impressed with its plan to distribute US$813 mln to shareholders, which works out to 37 US cents /
Assuming the plan goes ahead, STATS’ borrowings will rise to US$1.41 bln from US$683 mln and gross gearing to 2.2x from 0.5x. (As at end Sept ’07, STATS had cash of US$260 mln.) Those hoping to see Temasek take STATS private will just have to wait till the scheme is completed, a process that is likely to take months. (Temasek owns, at the close of its S$1.75 cash offer on May 18 ’07, 1,693,700,099
shares or 83.1% of STATS’ issued capital.)
Chemoil has appointed Clyde Michael Bandy as Chairman / CEO with immediate effect. Bandy, Lead Independent Director of Chemoil since Aug ’06, has >35 years of experience in the energy industry, mainly with the Texaco / Chevron group. This is positive for Chemoil after the tragic demise of founder Chairman / CEO R Chandran last week, except that investors are likely more interested in the possibility of Chemoil becoming a takeover candidate. As we had commented last week, it may be premature to speculate on this, given the legal
implications arising from Mr Chandran’s demise - bulk of Chemoil Chandran owned are held in a trust.
Reflecting the first official response to the SIA / Temasek / China Eastern saga, the Xinhua News Agency said on Saturday that
Source: Lim & Tan Securities